Compare RHI & PTCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RHI | PTCT |
|---|---|---|
| Founded | 1948 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 5.3B |
| IPO Year | N/A | 2013 |
| Metric | RHI | PTCT |
|---|---|---|
| Price | $26.80 | $77.48 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 7 | 17 |
| Target Price | $40.00 | ★ $73.76 |
| AVG Volume (30 Days) | ★ 2.5M | 2.3M |
| Earning Date | 10-22-2025 | 11-04-2025 |
| Dividend Yield | ★ 8.81% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 1.54 | ★ 8.94 |
| Revenue | ★ $5,458,499,000.00 | $1,779,150,000.00 |
| Revenue This Year | N/A | $128.32 |
| Revenue Next Year | $1.14 | N/A |
| P/E Ratio | $17.39 | ★ $8.64 |
| Revenue Growth | N/A | ★ 97.54 |
| 52 Week Low | $25.22 | $35.95 |
| 52 Week High | $78.41 | $87.50 |
| Indicator | RHI | PTCT |
|---|---|---|
| Relative Strength Index (RSI) | 42.15 | 54.29 |
| Support Level | $26.76 | $73.03 |
| Resistance Level | $28.01 | $79.03 |
| Average True Range (ATR) | 0.91 | 3.38 |
| MACD | 0.23 | -0.70 |
| Stochastic Oscillator | 55.58 | 29.37 |
Robert Half Inc was founded in 1948, Robert Half provides temporary, permanent, and outcome-based staffing for both in-person and remote positions in the finance and accounting, technology, legal, marketing, and administrative fields. Its subsidiary consulting arm, Protiviti, specializes in technology, risk, auditing, and compliance matters. The firm generates its sales inside the U.S. and is one of the specialized firms in the fragmented U.S. staffing industry. The firm generates annual revenue of around $7 billion.
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The Company views its operations and manages its business in one operating segment: life science.